Human Anti-Zika Virus IgG ELISA Kit SummaryThe Human Zika Virus IgG ELISA Kit is a 3.5 hour solid phase ELISA designed to measure Zika Virus IgG antibodies in human serum.
- High specificity with minimal cross-reactivity with Dengue Virus IgG antibodies
- High sensitivity
- Detection of Zika Virus IgG antibodies later in the infection when IgM antibodies may be undetectable
- Competitor comparison data
Principle of the Assay
This assay is an antigen-down enzyme immunoassay where a recombinant Zika Virus NS1 antigen is pre-coated onto a 96-well microplate and used to bind antibodies found in the sample. When the sample is added (such as human serum), antibodies found in the sample that recognize Zika Virus NS1 antigen bind the antigen coated plate and are retained in the well. After washing away unbound substances, an enzyme linked polyclonal antibody specific for human IgG is added to the wells. Following a wash to remove any unbound enzyme linked antibody, a substrate is added to the wells and color develops in proportion to the amount of IgG antibodies in the sample bound to the Zika Virus NS1 antigen. The color development is stopped and the intensity of the color is measured.
The potential for false positives due to Zika Virus NS1 antigen cross-reactive antibodies to related flaviviruses, such as Dengue Virus, is minimized by treatment of the samples. Samples are treated with a propriety treatment reagent prior to being added to the Zika Virus NS1 antigen coated plate. Sample specific background is determined by adding identically treated samples to an uncoated background plate and measuring the amount of IgG antibodies non-specifically bound to the well. To interpret results, net sample readings are calculated by subtracting each sample background plate reading from the Zika Virus NS1 antigen plate reading.
Intra-Assay Precision (Precision within an assay)
Three Zika Virus IgG antibody positive samples with high, middle, and low net O.D. were tested twenty four times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays)
Three Zika Virus IgG antibody positive samples with high, middle, and low net O.D. were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians.
|Intra-Assay Precision||Inter-Assay Precision|
This assay recognizes Zika Virus specific human IgG antibodies with minimal cross-reactivity of human Dengue IgG antibodies.
|Zika Virus IgG ELISA||# Zika Samples Testeda||Positive||Negative||Equivocal||% Positive|
|Zika Virus IgG ELISA||# Dengue Samples Testedc||Positive||Negative||Equivocal||% Positive|
Healthy Donor Samples
|Zika Virus IgG ELISA||# Healthy Donor Samples||Positive||Negative||Equivocal||% Positive|
aZika patient samples were collected from Colombia between 2015 and 2016 and determined to be positive based on EIA testing, according to the sample supplier.
bWhen tested without Treatment Reagent, these samples test positive for Zika Virus IgG, but are negative following Treatment Reagent treatment, indicating competitors A & E positive result from these samples are false positive.
cDengue patient samples were collected from Puerto Rico between 2012 and 2013 before Zika was introduced into Puerto Rico. On December 31, 2015, the United States reported the first PCR-confirmed case of locally acquired Zika infection in Puerto Rico.
Competitor A, E, and M kits have either high cross-reactivity with Dengue Virus IgG antibody or low sensitivity to Zika Virus IgG antibody. R&D Systems® Zika Virus IgG ELISA kit has high sensitivity and specificity to Zika Virus IgG antibody.
Background: Zika virus
Zika virus (ZIKV) is a mosquito-borne flavivirus found throughout tropical and subtropical regions, including East Africa, Southeast Asia, and the Pacific Islands, that is now causing large-scale outbreaks in the Americas (1, 2). This continuous geographic expansion of ZIKV poses a serious and increasing public health threat around the globe (1-4). Initially, ZIKV infection was thought to cause only mild illness, however it has now been linked to a rising number of severe neurological abnormalities and diseases including microcephaly, congenital abnormalities, and nonfetal illnesses such as Guillain-Barré syndrome, which emphasizes the importance of accurate ZIKV diagnostics (2, 4-6). Serological diagnosis is complicated by cross-reactivity among members of the Flavivirus genus (6). Because ZIKV, Dengue virus (DENV), and related flaviviruses, co-circulate in endemic regions and share high sequence similarity, there is a high possibility of IgM and IgG cross-reactivity in immunoassays (7). Current or past infections will often cause false positives requiring the need for follow-up testing and confirmation by a plaque-reduction neutralization (PRNT) assay. PRNT is a complicated method that takes considerable time and has limited availability (7, 8). In addition, antibodies present from past infection by Zika or other flaviviruses may enhance the risk of future ZIKV infections through antibody-dependent enhancement (ADE), which may lead to increased disease severity (9). There is a need for a simple serological test that displays high Zika specificity with minimal cross-reactivity with other flaviviruses.
- Waggoner, J.J. et al. (2016) J.Clin. Microbiol. 54:860.
- Song, B.H. et al. (2017) J. Neuroimmunol. 308:50.
- Fellner, C. (2016) PT. 41:778.
- Althouse, B.M. et al. (2016) PLoS Negl. Trop. Dis. 10:e0005055.
- Krauer, F. et al. (2017) PLoS Med. 14:e1002203
- Musso, D. et al. (2016) Clin. Microbiol. Rev. 29:487.
- Cabral-Castro, M.J. et al. (2016) J. Clin. Virol. 82:108.
- Sharma, A et al. (2017) Front. Microbiol. 8:110.
- Paul, L.M. et al. (2016) Clin. Transl. Immunol. 5:e117.
RT-PCR detects Zika viral RNA in serum during the acute phase of infection. RNA may be detected in serum within a week following the onset of symptoms. Zika Virus IgM ELISA kits detect IgM antibodies in serum beginning 4 to 5 days and up to 12 weeks after the onset of the virus. Zika Virus IgG ELISA kits detect IgG antibodies shortly after IgM antibodies are detected but are detectable for many years after the infection.
Background: Zika Virus IgG
Citation for Human Anti-Zika Virus IgG ELISA Kit
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Prevalence of Zika virus neutralizing antibodies in healthy adults in Vietnam during and after the Zika virus epidemic season: a longitudinal population-based survey
Authors: CT Nguyen, ML Moi, TQM Le, TTT Nguyen, TBH Vu, HT Nguyen, TTH Pham, THT Le, LMH Nguyen, MH Phu Ly, CFS Ng, T Takemura, K Morita, F Hasebe
BMC Infect. Dis., 2020;20(1):332. 2020-01-01
Can the Human Zika Virus IgG ELISA Kit, catalog # ZIK00, be use for diagnostic purposes?
No, it is not approved for diagnostic use. The Human Zika Virus IgG ELISA Kit is for Research Use Only.
Does this Human Zika Virus IgG ELISA Kit show cross-reaction to Dengue, West Nile, Yellow Fever, etc.?
Sample treatment minimizes cross reaction to dengue virus. Cross-reaction with other flavivirus such as West Nile or Yellow Fever is likely to be minimal, however has not been fully tested.
What is the formulation of the Treatment Reagent in Catalog # ZIK00, Human anti-Zika Virus IgG ELISA Kit?
This is a propriety formulation designed to reduce cross-reactivity caused IgG antibodies to Dengue, West Nile, Yellow Fever, and other related flavivirus.
What is the advantage of the Human anti-Zika Virus IgG ELISA Kit, catalog # ZIK00, when compared to PCR?
The viral load of Zika virus can be of low intensity and short duration, so detection via real-time RT-PCR has a very limited timeframe, and typically should be performed early (up to 10 days) after onset of illness.
Our Human Zika Virus IgG ELISA Kit can detect neutralizing IgG antibodies to Zika virus as early as 5 days after the onset of illness, and the IgG antibodies formed as immune response are expected to persist for many years, possibly lifelong, after infection.
Why are the background OD readings high with some patient samples when using the Human Zika Virus IgG ELISA kit?
It is normal to see high background OD readings with some patient samples when using the Human Zika Virus IgG ELISA kit. It is not known why this is observed.
Why is the Calculated Net O.D. for the Treatment Control > 0.100?
The Treatment Control is a flavivirus antibody control for cross-reactivity. A high reading may indicate error in preparation of the Treatment Control, or the Treatment Reagent is expired.
Does the kit contain live virus?
Purified Zika virus or other flaviviruses are not components in the kit. Some components in this kit contain human source materials and have been tested negative for antibodies to HIV 1&2, Hepatitis C and Hepatitis B surface antigen. However, material should be handled as potentially infectious.
Supplemental ELISA Products
Reviews for Human Anti-Zika Virus IgG ELISA Kit
There are currently no reviews for this product. Be the first to review Human Anti-Zika Virus IgG ELISA Kit and earn rewards!
Have you used Human Anti-Zika Virus IgG ELISA Kit?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image